Pipeline

Pipeline

Affimers secreted to extracellular region from AffyXell reinforce the immune modulating function by combining with innate immune modulators like cytokines.
Secreted Affimers can inhibit over-activated immune responses (Immune cells related to innate or adaptive immune system).
Affimers can be designed to different formats like monomer, dimer, trimer and etc. depending on the targets, and their half-life is also adjusted.

Cellular membrane-anchored Affimers can increase the cell-to-cell contact between AffyXell and target immune cells.
Affimers displayed on the surface of AffyXell reinforces the immune modulating function by activating receptors in target immune cells.
Affimers can be designed to conduct agonistic function through mediating more expansion and proliferation of Treg cells.

Development Stage

Product Candidate Target Indication Discovery Pre-clinical Phase1 Phase2 Phase3
AFX-001

SOT

Pre-clinical

GvHD

Pre-clinical

SOT

  • Stage : Discovery
  • Cell type : Engineered MSC
  • MoA : Suppression of T-cell mediated B-cell activation
  • Target : undisclosed
  • Dose Route : Intravenous Injection
  • Pre-clinical stage will begin in 2022

GvHD

  • Stage : Discovery
  • Cell type : Engineered MSC
  • MoA : Suppression of T-cell mediated B-cell activation
  • Target : undisclosed
  • Dose Route : Intravenous Injection
  • Pre-clinical stage will begin in 2022
AFX-002

MS

Discovery

MS

  • Stage : Discovery
  • Cell type : Engineered MSC
  • MoA : Inhibition of T-cell proliferation & cytokine production
  • Target : undisclosed
  • Dose Route : Intravenous Injection
  • Pre-clinical stage will begin in end of 2022